About Us

Welcome to MIORG, an innovative immuno-oncology research group dedicated to revolutionizing cancer treatment by harnessing the power of the immune system. Our ultimate goal is to help patients overcome resistance to cutting-edge immunotherapies, leading to better treatment responses and improved quality of life.

At the heart of our research strategy is a reverse translational approach. We begin by examining patient biopsies to uncover new biomarkers of resistance to immunotherapies. These invaluable biomarkers can serve as prognostic tools and targets for the development of novel adjuvant immunotherapies. We then meticulously validate the functions of these biomarkers in well-established in vivo and ex vivo models, setting the stage for groundbreaking drug development. Ultimately, our aim is to combine these innovative drugs with current immunotherapies, offering renewed hope to patients who previously had limited treatment options.

Our vision is to conduct world-class research that unlocks the full potential of immune checkpoint therapies (ICT) and cancer vaccines, particularly for patients with refractory conditions. Using metastatic melanoma as our primary cancer model, we endeavor to make a lasting impact in the field of immuno-oncology.

Employing state-of-the-art technologies such as Mass Cytometry and Digital Spatial Profiling (NanoString), our team analyzes solid and liquid biopsies alongside comprehensive clinical data, allowing us to delve deeper into the complex mechanisms of cancer and immunity.

At MIORG, we recognize the importance of sustainable development. We are committed to fostering a participatory society where everyone has equal access to the latest breakthroughs in immunotherapy prognostication and therapeutic development, both in Finland and across Europe. Our mission is not only to advance scientific discovery but also to ensure that these discoveries benefit all those touched by cancer.